Dexamethasone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dexamethasone: From Corticosteroid Anti-Inflammatory Therapy to Alopecia Areata
One-Sentence Summary
Dexamethasone is a potent synthetic glucocorticoid with broad anti-inflammatory and immunosuppressive use; this Evidence Pack does not contain specific original-indication or regulatory label data for the drug. The TxGNN model predicts it may be effective for Alopecia Areata, with 1 relevant RCT and 9 additional supporting publications (mostly cohort/case-series data on oral "mini-pulse" corticosteroid therapy) currently backing this direction; no clinical trial registered on ClinicalTrials.gov directly evaluates this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No data available (Evidence Pack contains no original indication or license text; dexamethasone is broadly known as a synthetic corticosteroid used across inflammatory/immune-mediated conditions) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this Evidence Pack. Based on known pharmacology, dexamethasone is a high-potency synthetic glucocorticoid; its anti-inflammatory and immunosuppressive efficacy is well established across corticosteroid-responsive conditions, and mechanistically this profile plausibly extends to alopecia areata.
Alopecia areata (AA) is a T-cell-mediated autoimmune disease in which cytotoxic T lymphocytes attack hair follicles that normally sit in an "immune-privileged" state. Dexamethasone acts through the glucocorticoid receptor to suppress T-cell activation and local inflammatory cytokine release — a mechanism directly relevant to halting the autoimmune attack driving AA.
This is not a novel hypothesis generated purely from embedding similarity: oral dexamethasone "mini-pulse" (Oral Mini-Pulse, OMP) therapy has been used in dermatology practice for over two decades as a treatment for moderate-to-severe AA, particularly in pediatric populations and in patients ineligible for newer JAK-inhibitor therapy. This existing real-world clinical practice pattern reinforces the biological plausibility of the TxGNN prediction.
Clinical Trial Evidence
The ClinicalTrials.gov query matched 14 registered trials containing "dexamethasone," but none directly evaluate dexamethasone for alopecia areata — all are unrelated regimens (e.g., multiple myeloma combination therapy, oncology supportive care, mesothelioma) rated low-relevance ("C") or off-topic by the relevance classifier.
Currently no related clinical trials registered for this specific indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36086930 | 2022 | RCT | Dermatologic Therapy | Randomized open-label trial in 30 children with severe AA comparing low-dose dexamethasone oral mini-pulse vs. DPCP contact sensitization |
| 39042154 | 2024 | Systematic Review / Network Meta-analysis | Archives of Dermatological Research | Compares systemic steroids, JAK inhibitors, and contact immunotherapy for severe AA; no single treatment shown clearly superior |
| 36461625 | 2023 | Review | Pediatric Dermatology | Literature review of pulse-dose corticosteroid dosing regimens and side effects for pediatric AA |
| 35330017 | 2022 | Prospective Cohort | Journal of Clinical Medicine | Real-world evidence on effectiveness/safety of dexamethasone mini-pulse therapy and factors associated with response in AA |
| 36070222 | 2022 | Retrospective Cohort (Multicentric) | Dermatologic Therapy | Oral dexamethasone mini-pulse therapy for moderate-to-severe AA, including totalis/universalis subtypes |
| 26179196 | 2015 | Case Series (long-term follow-up) | Dermatologic Therapy | 65 children/adolescents with severe AA treated with monthly oral dexamethasone pulses plus topical corticosteroid, median 96-month follow-up |
| 31579982 | 2019 | Case Series | Dermatologic Therapy | 73 pediatric patients with severe AA; comparison of 1-day vs 3-day IV dexamethasone pulse regimens plus topical clobetasol |
| 16707886 | 2006 | Comparative Clinical Study | Dermatology (Basel) | Compares efficacy, relapse rate, and side effects among three systemic corticosteroid regimens for extensive AA |
| 10535249 | 1999 | Clinical Study | The Journal of Dermatology | Twice-weekly 5 mg oral dexamethasone pulse in 30 patients with widespread AA; reports complete regrowth outcomes |
| 17656876 | 2002 | Clinical Review | Indian Journal of Dermatology, Venereology and Leprology | Discussion of dexamethasone pulse therapy utility and risk/benefit in extensive AA |
Finland Market Information
Dexamethasone is currently not marketed in Finland per this Evidence Pack, with 0 registered authorizations and no license records available.
Safety Considerations
Please refer to the package insert for safety information. This Evidence Pack contains no populated key warnings, contraindications, or drug interaction data (DDI query returned no results).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link between glucocorticoid immunosuppression and AA's T-cell-mediated pathology is well established, and one RCT plus multiple cohort/case-series studies support real-world use of dexamethasone oral pulse therapy in AA. However, no registered clinical trial directly evaluates this indication, and product-level regulatory/safety data are entirely absent, so full-scale progression is not yet warranted.
To proceed, the following is needed:
- Official package insert / regulatory label data (contraindications, warnings) — flagged as a Blocking data gap; required before any S1 safety pre-assessment
- Documented mechanism of action (MOA) from DrugBank or equivalent source — flagged as a High severity data gap
- Confirmation of Finland market/licensing status, since the drug currently shows 0 authorizations
- A prospective or registry-based trial specifically designed to evaluate dexamethasone (or OMP regimens) in AA, since existing evidence is exclusively retrospective/observational
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.